Accutar Biotechnology
Latest round
- Series A
Last raised
- Dec 2017
Total raised
- Undisclosed
Investors
- 3
About Accutar Biotechnology
Founded in 2015 in Brooklyn, US, Accutar Biotechnology Inc. specializes in the development of biopharmaceuticals aimed at addressing specific genetic mutations in cancer. Jie Fan, who has a background in various biotechnology ventures, serves as CEO and founder of the company.Accutar Biotech specializes in innovative biopharmaceutical solutions, focusing on the development and commercialization of targeted therapies aimed at oncology and other serious diseases. The company’s core product offerings include a suite of novel drug candidates designed to address specific genetic mutations in cancer cells, enhancing treatment efficacy while minimizing side effects. These therapies leverage cutting-edge technologies such as artificial intelligence and machine learning to optimize drug discovery and development processes. Its primary customer base comprises healthcare institutions, research organizations, and pharmaceutical partners across North America, Europe, and Asia-Pacific regions.Accutar Biotech generates revenue through strategic partnerships and collaborations with leading healthcare organizations and pharmaceutical companies. The company engages in B2B transactions, entering into agreements that may include milestone payments tied to the successful development of its drug candidates. Given its focus on oncology, transactions are likely structured around significant research and development agreements, in which Accutar provides access to its proprietary technologies in exchange for upfront fees and royalties on future product sales. Accutar’s flagship products are expected to command premium pricing due to their targeted approach and therapeutic value, positioning the company favorably within the competitive biopharmaceutical landscape.Accutar Biotechnology Inc. The company is focused on launching additional drug candidates designed to address specific genetic mutations in cancer by 2023. Additionally, Accutar aims to penetrate new markets in Europe and Asia-Pacific by the end of 2023, enhancing its global footprint in the biopharmaceutical sector.
Who invested in Accutar Biotechnology
3 investors across 2 rounds
See all investors in Accutar Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Accutar Biotechnology
Who invested in Accutar Biotechnology?
Accutar Biotechnology has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Accutar Biotechnology raised?
Accutar Biotechnology has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Accutar Biotechnology last raise money?
Accutar Biotechnology's most recent round on record is a Series A, in Dec 2017.
What does Accutar Biotechnology do?
Founded in 2015 in Brooklyn, US, Accutar Biotechnology Inc.
Where is Accutar Biotechnology headquartered?
Accutar Biotechnology is headquartered in Brooklyn, US.
Which VCs invest in companies like Accutar Biotechnology?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Accutar Biotechnology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Accutar Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.